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Abstract
Due to a shortage of donor hearts, rotary left ventricular assist devices (LVADs) are used to
provide mechanical circulatory support. To address the preload insensitivity of the constant
speed controller (CSC) used in conventional LVADs, we developed a preload-based Star-
ling-like controller (SLC). The SLC emulates the Starling law of the heart to maintain mean
pump flow (QP ) with respect to mean left ventricular end diastolic pressure (PLVEDm) as the
feedback signal. The SLC and CSC were compared using a mock circulation loop to assess
their capacity to increase cardiac output during mild exercise while avoiding ventricular suc-
tion (marked by a negative PLVEDm) and maintaining circulatory stability during blood loss
and severe reductions in left ventricular contractility (LVC). The root mean squared hemody-
namic deviation (RMSHD) metric was used to assess the clinical acceptability of each con-
troller based on pre-defined hemodynamic limits. We also compared the in-silico results
from our previously published paper with our in-vitro outcomes. In the exercise simulation,
the SLC increasedQP by 37%, compared to only 17% with the CSC. During blood loss, the
SLC maintained a better safety margin against left ventricular suction with PLVEDm of 2.7
mmHg compared to -0.1 mmHg for CSC. A transition to reduced LVC resulted in decreased
mean arterial pressure (MAP) andQP with CSC, whilst the SLC maintained MAP andQP .
The results were associated with a much lower RMSHD value with SLC (70.3%) compared
to CSC (225.5%), demonstrating improved capacity of the SLC to compensate for the vary-
ing cardiac demand during profound circulatory changes. In-vitro and in-silico results dem-
onstrated similar trends to the simulated changes in patient state however the magnitude of
hemodynamic changes were different, thus justifying the progression to in-vitro evaluation.
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Introduction
As patients implanted with rotary left ventricular assist devices (LVADs) progress through
different activity levels throughout the day, under-pumping or over-pumping may occur
which can lead to pulmonary congestion, impairment of right heart function and collapse of
the left ventricle (LV) [1]. Due to the lower preload sensitivity of rotary LVADs in the con-
ventional constant speed controller (CSC), when compared to the native heart [2], various
physiological control techniques have been developed to match pump output to physiologi-
cal requirements [3].
Starling and Visscher [4] demonstrated that LV contractility is proportional to LV end-
diastolic pressure (PLVED) via the Starling mechanism [5]. Accordingly, many LVAD physio-
logical control systems have attempted to duplicate the Starling mechanism while relying on
pressure and flow sensors [6–11]. For example, Bullister el al. [12] proposed a physiological
controller that maintained PLVED at a set point, thus increasing or decreasing cardiac output
to prevent respective changes in PLVED. Although this method was superior to CSC, the level
of resting PLVED alters significantly among individuals [13–15], while maintaining a fixed
PLVED during various circulatory perturbations would also require excessive pump speed var-
iations [16].
Recently, our group proposed a preload-based Starling-like controller (SLC) that could imi-
tate the native heart’s preload sensitivity [16]. The relation between pump flow output and pre-
load was sigmoid-like and could be formulated using a third-order polynomial equation [16].
This non-linear relationship between pump flow and ventricular preload gave the controller
the ability to make large adjustments in pump flow at low preloads in order to avoid ventricu-
lar suction, while reducing pump power at high preloads to avoid over pumping. Using a
numerical model of the cardiovascular system, it was demonstrated that a single control line
SLC outperformed a constant pulsatility ratio controller [8] and CSC. SLC resulted in higher
mean pump flow (QP) during exercise simulations, and prevented ventricular suction while
maintaining suitable hemodynamic parameters during simulations of blood loss and reduced
LV contractility (LVC).
For any newly proposed physiological control system, there is a hierarchy of studies that
can be performed to evaluate its efficacy, each having its own advantages and disadvantages.
While numerical models are commonly used as the first step during controller evaluation
due to the simplicity of model set-up and high reproducibility in results, it is difficult to
model the rotary blood pump dynamics accurately due to its complexity. As a result, simula-
tion results involving transient changes of pump speed to a particular perturbation or control
action as well as pump flow or speed pulsatility are less reliable. Evaluation of the control
techniques in a mock circulation loop (MCL) allows for real world use of an actual pump
and therefore a more accurate representation of the pump speed response to simulated
changes in patient state. Additionally, flow and pressure sensors can be used as feedback to
the controller, which is a more realistic situation than would be obtained using a numerical
model. As the steady-state response of the SLC system has only been evaluated in-silico,
further assessment using a more advanced bench top apparatus is required to observe the
dynamic effects of the pump and other circulatory compartments with this control method.
It is therefore of interest to enhance our previous numerical evaluation of the SLC by com-
paring the SLC system with the clinically used CSC in a validated MCL. In this work, both
the temporal and steady state responses of the SLC to three different test scenarios, including
moderate exercise, blood-loss and a major reduction in LVC, was assessed and compared
with CSC.
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Methodology
Description of the mock circulation loop
A physical MCL (Fig 1) including systemic and pulmonary circulations was used for this study
[17]. Four independent Windkessel chambers were employed to represent the lumped sys-
temic and pulmonary arterial and venous compliance. The systemic and pulmonary vascular
resistances were manipulated by socket valves (VMP025.03X.71, AKO Alb. Klein Ohio LLC,
USA). A series of electro-pneumatic regulators (ITV2030-012BS5, SMC Pneumatics, Tokyo,
Japan) and 3/2 way solenoid valves (VT325-035DLS, SMC Pneumatics, Tokyo, Japan) were
used to control ventricular systole (i.e. contractility, heart rate and systolic interval) and pas-
sively fill the heart chambers. A Starling mechanism was implemented for both the left and
right ventricles to actively control the ventricular pressure through the electro-pneumatic reg-
ulator current supply based on ventricular preload[18]. The mitral, aortic, tricuspid and pul-
monary valves were simulated using mechanical check valves. In this study, a mixture of water
and glycerol (60% water/40% glycerol by mass) was used as the working fluid to deliver asymp-
totic viscosity (3.5 mPa.s) and density (1100 kg/m3) similar to that of blood at 37˚C.
A VentrAssist LVAD (formally of Ventracor Ltd., Sydney, Australia) was used to support
the simulated failing heart in the MCL. The LVAD was cannulated with inflow connected to
the LV and outflow to the aorta. The left and right atrial, left and right ventricular, systemic
arterial, pulmonary arterial and LVAD inlet/outlet pressures were measured using silicone-
based transducers (PX181B-015C5V, Omega Engineering, Stamford, CT, USA). Systemic and
pulmonary flow rates were recorded using magnetic flow meters (IFC010, KROHNE, Duis-
burg, Germany) while LVAD flow rate was monitored by an ultrasonic flowmeter (TS410-
10PXL, Transonic Systems, NY, USA). All data were sampled at 2 KHz and recorded using a
dSPACE 1103 (dSPACE, Wixom, MI, USA). The MCL operational and control software were
developed in MATLAB/SIMULINK (The MathWorks, Natick, MA).
Preload-based Starling-like controller
The immediate response of the SLC was formulated as a sigmoid relationship between LV
stroke work and mean PLVED (PLVEDm) [19] to emulate the Starling mechanism of the
native heart. A control line was generated by a third-order polynomial function (Eq 1) fitted to
Guyton’s data [19]. This line relates the desired mean pump flow (QPRef ) to PLVEDm. In cases
when the lower preload sensitivity at high flows (compared with linear preload control) turned
out to be insufficient for any given patient, the preload sensitivity of the curve as a whole can
be increased. A scaling factor (K) was added to provide a means of altering the pump sensitiv-
ity to changes in PLVEDm, which makes Eq 1 adaptive with different preload sensitivities of
different patients [16].
QPRef ¼ ð0:0003  PLVED
3
m   0:0276  PLVED
2
m þ 0:9315PLVEDm   0:0928Þ  K ð1Þ
where PLVEDm represents the mean LV end-diastolic pressure. As the heart beat timing was
managed by the automatic MCL controller, the time of PLVED could be precisely determined.
By sampling the LV pressure at this moment, PLVED was acquired. The measured PLVED
was then passed through a low pass digital filter of 0.25 Hz to smooth the variation and acquire
the mean PLVED.
Any change in state (Fig 2) caused a deviation in the operating point from its original posi-
tion on the control line to other system lines. The controller then forced the operating point
back to the control line along a linear path, which conformed closely to the trajectories of the
linearized system lines. Changes in state were thus countered by moving the operating point
In-vitro preload-based Starling-like control
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up or down the control line. The pump speed was controlled to maintain the operating point
at its intersection between the control line and the system line.
Fig 2 also depicts a nonlinear relationship between the pump flow and the ventricular pre-
load. This non-linearity feature is one of the most important characteristics of the SLC; it gave
the controller the ability to deliver a very high preload sensitivity at low preloads (to avoid ven-
tricular suction) whilst a flat slope at high preloads ensured the avoidance of over-pumping.
This was in contrast to linear versions of preload control, such as Stevens et al. [9], which
Fig 1. (A) Schematic of the dual circuit mock circulation loop, and (B) Photograph of the MCL. LA, left atrium; MV, mitral valve; LV, left ventricle;
AoV, aortic valve; AoC, systemic arterial compliance; SQ, systemic flow meter; SVR, systemic venous resistance; SVC, systemic venous compliance; RA,
right atrium; TV, tricuspid valve; RV, right ventricle; PV, pulmonary valve; PAC, pulmonary arterial compliance; PQ, pulmonary flow meter; PVR, pulmonary
venous resistance; PVC pulmonary venous compliance; LVAD left ventricular assist device.
doi:10.1371/journal.pone.0172393.g001
Fig 2. Block diagram of the control system. CVS, cardiovascular system; VAD, ventricular assist device,
LVAD, left VAD; u, mean pulse-width modulation drive signal to the LVAD; HCVS, differential pressure between
the left ventricle and the aorta; CLn, Control line; S1, original state; S2 and S3, deviated states; QP, pump flow;
QP , mean pump flow;QPRef , The reference (desired) mean pump flow; PLVEDm, mean left ventricular end
diastolic pressure;ω, pump speed; o, mean pump speed; o
SP
, mean pump speed set-point; Grey circles,
position of operating points after changes in states; Black circles, position of operating points upon arriving at
the new steady state located at the intersection between the control line and the new system line. The
controller drives the changes in the operating points along the path indicated by the arrows along the new
system line; PLVEDm serves as the input to the preload controller (Eq 1);∑, 1-second moving average filter.
doi:10.1371/journal.pone.0172393.g002
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should not be considered as true Starling-like control. A more detailed description of the SLC
implementation can be found in [16].
Controller implementation
Pump speed was measured based on the back electromotive force of the VentrAssist motor
coils. A proportional—integral—derivative (PID) controller was developed to track the desired
pump flow, QPRef , by adjusting the average pump speed. Eq (2) defines the tracking PID trans-
fer function, automatically discretized by MATLAB/SIMULINK using a sampling period of
0.0005 s.











where o stands for mean pump rotational speed and S is the complex frequency.
The PID gains were tuned based on Ziegler–Nichols method [20] to achieve a 5% settling
time of 10 s and a 10% maximum overshoot of the final value, in response to a step change in
the mean QP set point from 1.80 L/min (corresponding to a pump speed of 1800 rpm, i.e. the
minimum operational speed) to the baseline value of 5.2 L/min. The resultant PID controller
gains, KP, KI and KD were set to 130 rpm.min/L, 162.5 rpm.min/L/s, and 58.5 rpm.s.min/L,
respectively, which provided settling and response times of 2.0 s and 4.5 s, with no overshoot.
Pump speed QP , and PLVED feedback signals were passed through a first-order transfer
function to obtain their mean values. The cutoff frequency of the filter was empirically set to
0.25 Hz to abate the short-term variability of the feedback signals without compromising the
system bandwidth. To minimize the tracking signal noise, a moving average filter with cutoff
frequency of 0.5 Hz was placed after QPRef but before the controller.
Experimental protocol
Both CSC and SLC were subjected to the same assessment protocol. The scaling factor (K) was
set to 1.0 for the SLC, while the corresponding speed of the CSC was set to 2100 rpm. Each
experiment started with a baseline LV failure condition at rest for 120 s to allow the system to
settle prior to performing a step change to one of the three test scenarios (i.e. exercise, blood
loss and reduced LVC). Upon transitioning to the new states, the experiments were continued
for another 120 s to achieve the post-transition steady state.
To simulate an exercise scenario, 700 mL of fluid was shifted from the systemic venous
compliance (SVC) chamber into the circulation, emulating the action of the muscle pump
in increasing venous return. Heart rate was increased from 60 to 90 bpm, while LVC was
increased from a dP/dtmax of 1040 to 1880 mmHg/s[21]. Systemic vascular resistance (SVR)
and pulmonary vascular resistance (PVR) were decreased from 1300 to 600 dyne.s.cm-5 and
from 110 to 40 dyne.s.cm-5 respectively.
To simulate blood loss, 300 mL fluid was shifted from the circulation into the systemic
venous compliance chamber to emulate blood flowing into the legs. SVR and PVR were
increased from 1300 to 1635 dyne.s.cm-5 and from 110 to 210 dyne.s.cm-5 respectively, to sim-
ulate vasoconstriction.
A major reduction in LVC was simulated by eliminating the LV contractility using the LV
electro-pneumatic regulators. For all simulations, the change of parameters was immediate
and simultaneous; however, the fluid shifts were completed over a longer duration (but no
more than 20 seconds) due to the MCL dynamics. In this MCL, fluid shifts from the SVC to
In-vitro preload-based Starling-like control
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the heart and vice versa were controlled by adjusting the air pressure in the SVC chamber
using a manual ball valve. The key MCL parameters used to mimic baseline, exercise, blood-
loss, and reduced LVC conditions are listed in Table 1.
Performance evaluation
The performance of SLC and CSC was compared by observing the changes in QP , mean total
cardiac output (CO), mean arterial pressure (MAP) and left atrial pressure (Pla) while transi-
tioning from the baseline state to exercise, blood-loss, and reduced LVC scenarios. In this
study, a performance metric to provide a quantitative comparison aspect of clinical context
with each controller was employed. Accordingly, the average deviation per second of the
MAP, PLVED, and CO from the respective predefined physiological limits (Table 2), that
denoted the root mean square hemodynamic deviation (RMSHD), was determined[22, 23]. A
lower RMSHD promises a better clinical performance of the controller [22].
To calculate RMSHD, let yx stand for any of the three previously mentioned hemodynamic
variables (i.e. MAP, PLVED, CO), and let LLx and ULx define the lower and upper limits of the
safe operating bound for that variable, respectively. The normalized square deviation









yxðtÞ   ULx; yxðtÞ > ULx
0; LLx < yxðtÞ < ULx





Table 1. Key MCL parameters for mimicking different hemodynamic conditions.
Variable Baseline Exercise Blood-loss LVC Reduction
Heart rate (bpm) 60 90 65 60
SVR (Dynes.s/cm5) 1300 600 1635 1300
PVR (Dynes.s/cm5) 110 40 210 110
Circulation fluid shift - - - SVC! RV (700mL) RV! SVC (300mL) - - -
Clv (mmHg/s) 1040 1880 1040 25
PVR, pulmonary vascular resistance; SVR, systemic vascular resistance; RV, right ventricle; SVC, systemic venous compliance chamber; LV, left ventricle;
LVC, LV contractility; Clv, LV end systolic elastane.
doi:10.1371/journal.pone.0172393.t001
Table 2. Upper and lower limits for the key hemodynamic variables.
Variable (unit) Lower Limit Upper Limit
Mean arterial pressure (mmHg) 80 120
Left ventricular end diastolic pressure (mmHg) 2 15
Cardiac output: Rest and hemorrhage (L/min) 4 6
Cardiac output: Exercise (L/min) 6 11
Deviations outside of these bounds were recorded and used to compare the physiological performance of
the control systems.
doi:10.1371/journal.pone.0172393.t002
In-vitro preload-based Starling-like control
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Results were obtained to compare the performance of SLC and CSC systems under various
hemodynamic perturbations. During the exercise simulation, starting hemodynamics were
similar between SLC and CSC systems. At the onset of exercise, a drop in SVR and PVR
resulted in an initial fall in systemic arterial pressure (PSA) and a rise in pump flow (QP) despite
an increase in heart rate with both controllers (Table 3). After a few seconds, fluid was shifted
from the systemic venous compliance into the RV, which subsequently activated the ventricu-
lar Starling mechanism, causing both left and right ventricular contractility to increase. Conse-
quently, PSA and QP increased gradually before settling to a level higher than their baseline
values with SLC and CSC.
Fig 3 clearly showed that both the SLC and CSC demonstrated similar hemodynamic tran-
sition patterns; however, the magnitude of hemodynamic changes was greater with the SLC,
especially for QP (Table 3). This was due to the increased pump speed with the SLC (from
2103 to 2295 RPM) compared to that of the CSC (constant at 2100 RPM), with the Starling-
like relationship of the SLC during the transition to exercise shown in Fig 4. The improved
performance of the SLC can be characterized by observing the final steady-state results shown
in Table 3, which showed increased QP with the SLC (7.1 L/min) compared to CSC (6.2 L/
min) after the exercise condition had settled. However, it should be noted that total CO was
similar between the two controllers, and may indicate increased ventricular work with CSC
compared to SLC. PLVEDm was decreased with the SLC (13.8 mmHg) compared to CSC (15.1
mmHg) during exercise, which also indicates reduced load on the LV. Moreover, the value of
Table 3. In-silico and in-vitro hemodynamic data at baseline (rest) and exercise for constant speed mode and Starling-like control.
Variable Unit In-Silico 1 In-Vitro









o rpm 2600 2600 0.0 2600 2980 14.6 2100±13 2100±15 0.0 2103±18 2295±18 9.1
MAP mmHg 103 101 -1.9 103 104 1.0 89±0.2 95±0.3 6.7 89±0.3 96±0.2 7.9
PLA mmHg 9 21 133.3 9 19 111.1 10.9±0.1 16.4±0.1 50.4 10.8±0.1 14.2±0.1 31.5
PLVEDm mmHg 7.4 18.9 155.4 7.4 15.6 110.8 9.5±0.1 15.3±0.2 61.1 9.3±0.1 13.8±0.4 48.4
CO L/min 5.6 8.9 58.9 5.6 9.2 64.3 5.2±0.1 10.1±0.1 94.2 5.2±0.1 10.4±0.1 100.0
QP L/min 5.6 6.7 19.6 5.6 8.5 51.8 5.2±0.1 6.2±0.1 19.2 5.2±0.1 7.1±0.2 36.5
RMSHD % 0.0 11.2 - - - 0.0 0.6 - - - 0.0 26.4 - - - 0.0 12.7 - - -
o, mean pump speed; MAP, mean arterial pressure; PLA , mean left atrial pressure; PLVEDm, mean left ventricular end diastolic pressure; CO, mean cardiac
output; QP, pump flow;QP , mean pump flow; RMSHD, root mean squared hemodynamic deviation.
1 Results in the in-silico section were extracted from [16].
doi:10.1371/journal.pone.0172393.t003
In-vitro preload-based Starling-like control
PLOS ONE | DOI:10.1371/journal.pone.0172393 February 17, 2017 7 / 15
RMSHD for the SLC was 12.7%, less than the half of the value achieved when utilizing CSC
(RMSH of 26.4%), indicating a significantly better clinical performance for the SLC.
When comparing in-vitro and in-silico results (Table 3), it was inferred that the trend in all
hemodynamic variables remained the same when comparing SLC and CSC; however, the mag-
nitude of changes were different due to the different platform settings and starting hemody-
namics and pump speeds. In the numerical model the speed changes for SLC were higher
(14.6%) when compared to in-vitro testing (9.1%), which resulted in higher QP changes in-sil-
ico. Furthermore, cardiac output increased in-silico and in-vitro to similar levels (by 5.4% and
5.8% respectively) with SLC, indicating a reduction in ventricular work with SLC. MAP
changes were higher in-vitro for both CSC and SLC (6.7% and 7.9% increase respectively)
when compared to the numerical model (1.9% decrease with CSC and 1% increase with SLC).
Fig 3. Transient response of LVAD speed, systemic pressure, and pump flow during a simulated
transition from baseline to exercise. SLC, Starling-like control; CSC, constant speed control; PSA, systemic
arterial pressure; QP, pump flow.
doi:10.1371/journal.pone.0172393.g003
Fig 4. The relationship between mean pump flow and mean PLVED while transitioning from baseline
to exercise, for the constant speed mode and Starling-like control. SLC, Starling-like control; CSC,
constant speed control; QP, pump flow; CLn, control line (1); OP1, initial operational point; OP2, final
operational point.
doi:10.1371/journal.pone.0172393.g004
In-vitro preload-based Starling-like control
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During the blood loss simulation, SVR and PVR were increased which resulted in increased
MAP and a reduction in QP (Fig 5 and Table 4) with both CSC and SLC. As the process
included a gradual shift in fluid over approximately 20 s, it can be assumed that the circulation
volume was almost constant during the first few seconds of the transition. As the fluid shifted
from the circulation to the SVC chamber, the mean circulatory filling pressure, systemic
arterial pressure and QP all decreased with the SLC and CSC. However, the magnitude of
hemodynamic changes varied greatly between systems. For instance, after the blood loss was
completed, QP only decreased from 5.1 to 3.6 L/min with CSC which resulted in PLVEDm of
-0.1 mmHg, indicating LV suction (Table 4). In contrast, the SLC reduced mean pump speed
from 2096 to 1793 RPM, which reduced QP from 5.1 to 2.1 L/min and maintained PLVEDm
above 2 mmHg, thus avoiding LV suction. This is evident in the relationship between QP and
PLVEDm in Fig 6. Thus, it can be concluded that the SLC was able to reduce QP adequately to
maintain an adequate safety margin against LV suction while the CSC could not. Meanwhile,
Fig 5. Transient response of LVAD speed, systemic pressure, and pump flow during a simulated
transition from baseline to blood-loss. SLC, Starling-like control; CSC, constant speed control; PSA,
systemic arterial pressure; QP, pump flow.
doi:10.1371/journal.pone.0172393.g005
Table 4. In-silico and in-vitro hemodynamic data at baseline (rest) and blood-loss for constant speed mode and Starling-like control.
Variable Unit In-Silico 1 In-Vitro

















o rpm 2600 2600 0.0 2600 2115 -18.7 2100±13 2100±20 0.0 2096±19 1793±25 -14.6
MAP mmHg 103 96 -6.8 103 84 -18.4 91±0.2 92±0.2 1.1 92±0.3 81±0.3 -13.6
PLA mmHg 9 4 -55.5 9 5.4 -40.0 9.2±0.1 1.4±0.0 -84.8 10.0±0.1 3.2±0.1 -68.0
PLVEDm mmHg 7.4 -0.4 -105.4 7.4 4.9 -33.8 7.1±0.1 -0.1±0.2 -101.4 8.3±0.1 2.7±0.1 -67.5
CO L/min 5.6 5.3 -5.4 5.6 4.4 -21.4 5.2±0.1 3.9±0.1 -25.0 5.3±0.1 3.7±0.1 -30.2
QP L/min 5.6 5.3 -5.4 5.6 3.7 -33.9 5.1±0.1 3.6±0.2 -29.4 5.1±0.1 2.1±0.1 -58.8
RMSHD % 0.0 11.2 - - - 0.0 0.6 - - - 0.0 26.4 - - - 0.0 12.7 - - -
o, mean pump speed; MAP, mean arterial pressure; PLA , mean left atrial pressure; PLVEDm, mean left ventricular end diastolic pressure; CO, mean cardiac
output; QP, pump flow;QP , mean pump flow; RMSHD, root mean squared hemodynamic deviation.
1 Results in the in-silico section were extracted from [16].
doi:10.1371/journal.pone.0172393.t004
In-vitro preload-based Starling-like control
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RMSHD was 199% for CSC, showing a dramatic reduction in performance compare with the
SLC system (RMSHD value of 58%).
Similar to the exercise scenario, in-vitro results showed similar trends when compared to
the in-silico results for both CSC and SLC (Table 4). Although the magnitude of changes in
hemodynamics in response to blood loss were different between in-vitro and in-silico simula-
tions, the differences between CSC and SLC in terms of percentage changes were comparable.
The SLC decreased pump speed by 18.7% and 14.6% when evaluated in-silico and in-vitro
respectively. Differences in QP changes between CSC and SLC were similar both in-silico and
in-vitro with the SLC decreasing QP by 28.5% and 29.4% respectively.
During a major reduction in LVC with CSC, QP decreased from 5.1 to 4.8 L/min (Figs 7
and 8). Although this was within our clinically acceptable ranges, the SLC was able to maintain
QP at 5.1 L/min through an increase in pump speed from 2096 to 2210 RPM (Table 5). How-
ever, the SLC appeared to have an increased settling time during the major reduction in LVC
compared to other simulations (Fig 7), which can be attributed to the elimination of the flow-
Fig 6. The relationship between mean pump flow and mean PLVED while transitioning from baseline
to blood-loss, for the constant speed mode and Starling-like control. SLC, Starling-like control; CSC,
constant speed control; QP, pump flow; CLn, control line (1); OP1, initial operational point; OP2, final
operational point.
doi:10.1371/journal.pone.0172393.g006
Fig 7. Transient response of LVAD speed, systemic pressure, and pump flow during a simulated
transition from baseline to reduced left ventricular contractility. SLC, Starling-like control; CSC,
constant speed control; PSA, systemic arterial pressure; QP, pump flow.
doi:10.1371/journal.pone.0172393.g007
In-vitro preload-based Starling-like control
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balancing ventricular Starling response, along with the dynamics of the systemic and pulmo-
nary circulations connected in series.
Similar to the previous experiments the CSC and SLC exhibited similar responses to a tran-
sition from baseline to LVC reduction when comparing in-silico and in-vitro results (Table 5).
The SLC maintained hemodynamic parameters during an LVC reduction by increasing pump
speed by 3.8% (in-silico) and 5.4% (in-vitro), which subsequently reduced LV preload when
compared to CSC.
Discussion
To date, various physiologically responsive controllers have been proposed for LVAD support
[3] to cater for the varying metabolic demand of the pump-assisted patients while undergoing
different activities in their daily lives. Gaddum et al (2014) and Schima et al (2006) utilized pul-
satile-based controllers to imitate the native Starling flow sensitivity [7, 10]. Although their
Fig 8. The relationship between mean pump flow and mean PLVED while transitioning from baseline
to reduced left ventricular contractility, for the constant speed mode and Starling-like control. SLC,
Starling-like control; CSC, constant speed control; QP, pump flow; CLn, control line (1); OP1, initial operational
point; OP2, final operational point.
doi:10.1371/journal.pone.0172393.g008
Table 5. In-silico and in-vitro hemodynamic data at baseline (rest) and reduced LV contractility scenario (LVC) for constant speed mode and Star-
ling-like control.
Variable Unit In-Silico 1 In-Vitro
Constant Speed Starling-like Constant Speed Starling-like
Baseline LVC % change Baseline LVC % change Baseline LVC % change Baseline LVC % change
o rpm 2600 2600 0.0 2600 2700 3.8 2100±13 2100±1 0.0 2096±17 2210±10 5.4
MAP mmHg 103 97 -5.8 103 103 0.0 92±0.1 86±0.1 -6.5 92±0.3 92±0.2 0.0
PLA mmHg 9 12 33.3 9 9 0.0 9.2±0.1 9.8±0.1 6.5 9.7±0.1 8.6±0.1 -11.3
PLVEDm mmHg 7.4 11 48.6 7.4 7.4 0.0 7.7±0.1 9.2±0.1 19.5 8.0±0.1 7.9±0.1 -1.3
CO L/min 5.6 5.2 -7.1 5.6 5.6 0.0 5.2±0.1 4.8±0.1 -7.7 5.3±0.1 5.2±0.1 -1.9
QP L/min 5.6 5.2 -7.1 5.6 5.6 0.0 5.1±0.1 4.8±0.1 -5.9 5.1±0.1 5.1±0.1 0.0
RMSHD % 0.0 0.0 - - - 0.0 0.0 - - - 0.0 0.0 - - - 0.0 0.0 - - -
o, mean pump speed; MAP, mean arterial pressure; PLA , mean left atrial pressure; PLVEDm, mean left ventricular end diastolic pressure; CO, mean cardiac
output; QP, pump flow;QP , mean pump flow; RMSHD, root mean squared hemodynamic deviation.
1 Results in the in-silico section were extracted from [16].
doi:10.1371/journal.pone.0172393.t005
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results demonstrated the strength of pulsatility control over CSC, there are several limitations
associated with their controllers. The main issue with the proposed pulsatility controller was
that pump pulsatility (flow, current, pressure gradient, or speed) is a consequence of LV con-
traction, which is dependent on LV preload. In cases of severe LV failure, the LV does not
possess sufficient capacity to influence pulsatility and thus the dynamic range of pulsatility
indexes is small. More importantly, pulsatility control is not feasible in cases with zero LV con-
tractility. In addition, our published numerical studies demonstrated the limitations of those
pulsatility index control strategies during exercise, blood loss, and left ventricular contractility
reduction that agree with the clinical studies [16, 24]. Such limitations did not exist with our
SLC system, as demonstrated by the capacity to restore hemodynamics even with complete
elimination of LVC (and thus pulsatility).
A Starling-like LVAD control method was developed by Stevens et al. [9] in 2011, which
used a conventional PID (proportional-integral-derivative) technique to regulate pump flow
as a function of left atrial pressure. The Starling mechanism was approximated with a linear
relation between average left atrial pressure (PLA) and mean pump flow (QP) where the gradi-
ent between these two variables (slope of the line) alters to respond to different physiological
conditions. However, adding an automatic sensitivity regulator necessitated an extra PI con-
troller cascaded with the original PID that increased the system complexity and increased the
cost of gain tuning. On the contrary, our SLC demonstrated similar suction prevention and
exercise capacity to those presented by Stevens et al without the requirement of an additional
PI controller cascade. Furthermore, Stevens’ model did not include a flat slope at higher pre-
load values, which is crucial for Starling-like controllers to avoid over-pumping at high
preloads.
Compared to CSC, the SLC evaluated in this study was able to synchronize systemic and
pulmonary flow rates irrespective of variations in venous return by emulating the Starling
mechanism of the native heart. The SLC produced a lower PLVED than CSC during exercise
and reduced LV contractility scenarios, thus potentially providing improved ventricular
unloading. Meanwhile, there is evidence that LV suction under CSC may cause a significant
reduction in right ventricular performance through endocardial damage and septal shift [8,
25]. Improved flow-balancing with the SLC may reduce the incidence of pulmonary conges-
tion; an incident that may otherwise lead to long-term right ventricular failure [1]. Meanwhile,
maintaining adequate LV preload with the SLC will also prevent intermittent LVAD flow
stoppages and ventricular arrhythmias associated with left ventricular suction, even in severe
blood loss conditions as simulated in this study.
When simulating a major reduction in LVC, we observed increased preload with CSC
whilst MAP dropped. The SLC responded to such rise in preload by increasing the pump
speed and flow, which subsequently returned the preload to its previous value. The results
showed little benefit of the SLC over constant speed mode, evident by zero RMSHD value for
the both methods. Under the SLC, both QP and MAP were maintained at 5.1 L/min and 92
mmHg respectively, whilst we saw a decrease in mean pump flow to 4.8 L/min with MAP at 86
mmHg for the fixed speed operational mode. The results showed CSC is in fact suitable to tol-
erate LVC reduction, while the SLC only provides minimal benefits. Meanwhile, the long set-
tling time with the SLC during LVC reduction could be considered a limitation with our
controller; however, no adverse events (ventricular suction, venous congestion) occurred.
Results in the present study clearly established similar trends between in-silico and in-vitro
testing [16], with the SLC demonstrating superior performance when compared to CSC in all
scenarios in both evaluation platforms. The absence of the autonomic baroreflex mechanism
in the MCL resulted in a smaller increase in mean arterial and left atrial pressures compared to
In-vitro preload-based Starling-like control
PLOS ONE | DOI:10.1371/journal.pone.0172393 February 17, 2017 12 / 15
the numerical simulation; however differences between the two platforms were minor. During
the blood loss simulation, large spikes in pump flow indicating LV suction occurred with CSC,
which was in agreement with our previously published numerical study [16]. Although in-sil-
ico and in-vitro results showed similar trends during changes in patient state, there were differ-
ences in the magnitude of changes, which could be attributed to differences in simulated
patient hemodynamics, starting pump speeds, the lack of a baroreflex in-vitro, and the real-
world use of a pump and sensors in-vitro. Providing an exact replica between both simulation
platforms is difficult, and the focus of this evaluation paper was to demonstrate the feasibility
of our SLC to prevent adverse events under various simulated patient states in an MCL. A full
comparison between the two testing benchtops, although interesting, is beyond the scope of
this in-vitro physiological control work.
Although this study focused on using a single preload control line, a full controller should
be capable of adapting to variations in the left ventricle (LV) function by automatically adjust-
ing the scaling factor. The process of adapting curves and changing the scaling factor was ini-
tially introduced by Salamonsen et al (2012)[8] and Gaddum et al (2014)[7]. At the time of
LVAD implantation, adjustments to different Starling curves ensures optimal LV unloading
for each specific patient with the clinician input to match the initial control line with each indi-
vidual. After LVAD implantation, changes in the preload sensitivity (i.e. scaling factor) of the
control line might still be necessary to adapt to longer term changes, such as with the progres-
sion of the LV disease.
Conclusion
Our in-vitro study clearly established the superiority of the preload-based SLC over CSC while
transitioning from the baseline state to exercise, blood loss, and a major reduction in LVC.
The SLC was able to provide a greater pump flow and cardiac output during exercise as com-
pared to the conventional CSC, with less loading on the heart. In addition, it maintained a
better safety margin against LV suction during blood loss. Although the CSC maintained suit-
able hemodynamics during a reduction in LVC, the SLC maintained almost perfect hemody-
namic stability. The SLC has the potential to improve patient outcomes substantially through
improved cardiac preservation and increased responsiveness to the patient’s requirements in
the multiple physiological conditions faced by the LVAD patient—both in hospital and at
home.
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